Pfizer Inc
NYSE: PFE
$25.65
+$0.52 (+2.1%)
Closing Price on November 22, 2024
PFE Articles
Judging by the most shorted stocks traded on the New York Stock Exchange between the March 15 and March 29 settlement dates, short sellers were focused on a couple of favorites.
Published:
Last Updated:
Pfizer shares took a small step back on Monday despite announcing positive results from a late-stage trial. The pullback seems to be the product of overall market sentiment as opposed to these...
Published:
Last Updated:
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Judging by the most shorted stocks traded on the New York Stock Exchange between the February 28 and March 15 settlement dates, short sellers were stocking up on some favorites.
Published:
Last Updated:
DowDuPont, Goldman Sachs, 3M Company, and Pfizer pushed the Dow lower again Friday.
Published:
Last Updated:
Pfizer shares slipped slightly on Friday after the pharma giant announced results from its Chantix/Champix smoking cessation study in adolescents.
Published:
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
As of the most recently reported period, short sellers still favored just two Dow stocks, General Electric and Intel, above all others.
Published:
Last Updated:
The Dow wobbled around Thursday and looks set to close very near the break-even line as J&J, Pfizer, Caterpillar, and McDonald's pushed higher.
Published:
Last Updated:
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Published:
Last Updated:
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
Published:
Last Updated:
Pfizer, UnitedHealth, Disney, and Johnson & Johnson lifted the DJIA on Friday.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Published:
Last Updated:
These are the 10 stocks tracked by 24/7 Wall St. that received multiple analyst rating upgrades or price target hikes of Wednesday, January 31, 2018.
Published:
Last Updated: